153 related articles for article (PubMed ID: 32272784)
1. The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.
Berning P; Hennemann C; Tulotta C; Schaefer C; Lechtape B; Hotfilder M; El Gourari Y; Jürgens H; Snaar-Jagalska E; Hempel G; Dirksen U; Potratz J
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272784
[TBL] [Abstract][Full Text] [Related]
2. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
Potratz JC; Saunders DN; Wai DH; Ng TL; McKinney SE; Carboni JM; Gottardis MM; Triche TJ; Jürgens H; Pollak MN; Aparicio SA; Sorensen PH
Cancer Res; 2010 Nov; 70(21):8770-81. PubMed ID: 20959493
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.
Potratz J; Tillmanns A; Berning P; Korsching E; Schaefer C; Lechtape B; Schleithoff C; Unland R; Schäfer KL; Müller-Tidow C; Jürgens H; Dirksen U
Mol Oncol; 2016 May; 10(5):677-92. PubMed ID: 26739507
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
6. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
[TBL] [Abstract][Full Text] [Related]
8. The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.
Cazes A; Childers BG; Esparza E; Lowy AM
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454943
[TBL] [Abstract][Full Text] [Related]
9. When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
Baird AM; Easty D; Jarzabek M; Shiels L; Soltermann A; Klebe S; Raeppel S; MacDonagh L; Wu C; Griggs K; Kirschner MB; Stanfill B; Nonaka D; Goparaju CM; Murer B; Fennell DA; O'Donnell DM; Barr MP; Mutti L; Reid G; Finn S; Cuffe S; Pass HI; Opitz I; Byrne AT; O'Byrne KJ; Gray SG
Front Endocrinol (Lausanne); 2019; 10():89. PubMed ID: 30863365
[TBL] [Abstract][Full Text] [Related]
10. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
[TBL] [Abstract][Full Text] [Related]
11. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
12. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
[TBL] [Abstract][Full Text] [Related]
13. Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.
Chakedis J; French R; Babicky M; Jaquish D; Mose E; Cheng P; Holman P; Howard H; Miyamoto J; Porras P; Walterscheid Z; Schultz-Fademrecht C; Esdar C; Schadt O; Eickhoff J; Lowy AM
Oncotarget; 2016 Jul; 7(29):45959-45975. PubMed ID: 27323855
[TBL] [Abstract][Full Text] [Related]
14. Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.
Wang X; Yennawar N; Hankey PA
Cell Commun Signal; 2014 Apr; 12():28. PubMed ID: 24739671
[TBL] [Abstract][Full Text] [Related]
15. Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Int J Clin Exp Med; 2015; 8(11):20778-86. PubMed ID: 26885001
[TBL] [Abstract][Full Text] [Related]
16. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
17. RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.
Park JS; Choi HI; Kim DH; Kim CS; Bae EH; Ma SK; Kim SW
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31690042
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
19. HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.
Ruiz-Torres SJ; Benight NM; Karns RA; Lower EE; Guan JL; Waltz SE
Oncotarget; 2017 Aug; 8(35):58918-58933. PubMed ID: 28938607
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
